07 November 2016
EMA/CAT/783686/2016
Inspections, Human Medicines Pharmacovigilance & Committees Division

Committee for Advanced Therapies (CAT)

Minutes of the meeting on 06-07 October 2016

Chair: Paula Salmikangas - Vice-chair: Martina Schüßler-Lenz

06 October 2016, 09:00 – 18:00, room 03-E
07 October 2016, 09:00 – 13:00, room 03-E

Disclaimers

Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, the minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introduction 5

1.1. Welcome and declarations of interest of members, alternates and experts 5

1.2. Adoption of agenda 5

1.3. Adoption of the minutes 5

2. Evaluation of ATMPs 5

2.1. Opinions 5

2.2. Oral explanations 5

2.3. Day 180 List of outstanding issues 5

2.4. Day 120 Lists of questions 5

2.5. Day 80 assessment reports 6

2.6. Ongoing initial full application 6

2.7. New applications 6

2.8. Withdrawal of initial marketing authorisation application 6

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation no. 726/2004 6

2.10. GMP and GCP inspections requests 6

2.11. Type II variations 6

2.11.1. Glybera – Alipogene tiparvovec; *Orphan*; EMA/H/C/002145/II/56 6

2.11.2. Strimvelis - Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence; *Orphan*; EMA/H/C/003854/II/01/G 6

2.12. Other post-authorisation activities 7

2.12.1. Glybera - Alipogene tiparvovec; Orphan; EMEA/H/C/002145 - SOB 002.5 7

2.12.2. Holoclar - *ex vivo* expanded autologous human corneal epithelial cells containing stem cells; *Orphan*; EMA/H/C/002450/R/0008 7

2.12.3. Strimvelis – autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence; *Orphan*; EMA/H/C/003854/005 – REC005 7

3. Certification of ATMPs 7

3.1. Opinions 7

3.2. Day 60 evaluation reports 7

3.3. Ongoing initial application 8

3.4. New applications 8

4. Scientific Recommendation on Classification of ATMPs 8

4.1. New requests – appointment of CAT Co-ordinators 8

4.1.1. Bone marrow derived mesenchymal cells (MSCs); EMA/H004688 8

4.2. Day 30 Co-ordinators' first reports 8

4.2.1. Autologous bone marrow-derived non-haematopoietic stem cells; EMA/H004661/001 8
4.2.2. Anti-BCMA (B-cell Maturation Antigen) Chimeric Antigen Receptor T cells; EMA/H004662/001 8
4.2.3. Wharton's jelly derived mesenchymal stem cells; EMA/H004676/001 8
4.2.4. Modified vaccinia virus Ankara encoding human mucin 1 and interleukin 2; EMA/H004658/001 9
4.2.5. Autologous human adipose mesenchymal stromal cells; EMA/H004677/001 9
4.2.6. Autologous skin cell suspension; EMA/H004679/001 9
4.2.7. Rilimogene galvacirepved and rilimogene glafolivec; EMA/H004657/001 9
4.3. Day 60 Co-ordinators' revised reports following List of Questions 10
4.4. Finalisation of procedures 10
4.4.1. Genetically-modified *Lactobacillus reuteri* bacteria, with a plasmid containing the gene for human CXCL12-1a with an inducible promoter; EMA/H004673/001 10
4.4.2. Autologous cells of stromal vascular fraction (SVF) and autologous adipose derived stem cells; EMA/H004683/001 10
4.4.3. Tumour selectively replicating oncolytic adenovirus expressing tumor necrosis factor alpha (TNFα) and interleukin 2 (IL2); EMA/H004684/001 10
4.4.4. Natural killer receptor-2 autologous engineered T cells; EMA/H004680/001 10
4.4.5. DNA plasmid vectors encoding for human papillomavirus type 16 consensus E6 and E7 antigens and human papillomavirus (HPV) type 18 consensus E6 and E7 antigens; EMA/H004685/001 11
4.5. Follow-ups and guidance 11
4.5.1. Informal classification discussion on request of a National Competent Authority 11
5. Scientific Advice 11
5.1. New requests – appointment of CAT Co-ordinators 11
5.2. CAT Rapporteurs' reports 11
5.3. List of issues 11
5.4. Finalisation of Scientific Advice procedures 11
5.5. Follow-up of Scientific Advice procedures 11
6. Pre-Authorisation Activities 11
6.1. Paediatric investigation plans 11
6.2. ITF briefing meetings in the field of ATMPs 11
6.3. Priority Medicines (PRIME) – Eligibility requests 11
6.3.1. **Month 0 - Start of the procedure** 11
6.3.2. **Month 1 – Discussion of eligibility** 12
6.3.3. **Month 2 – Recommendation for eligibility** 12
6.3.4. **Month 3 - Nomination of Rapporteurs** 12
6.3.5. **Ongoing support** 12

7. Organisational, regulatory and methodological matters 12

7.1. Mandate and organisation of the CAT 12

7.1.1. Strategic Review & Learning meeting 12

7.1.2. Recommendation on criteria for competence and expertise of CAT members and alternates 12

7.1.3. GMP requirements for ATMPs 12

7.1.4. Combination packs requirements for ATMPs 13

7.2. Coordination with EMA Scientific Committees 13

7.2.1. Committee for Medicinal Products for Human Use (CHMP) 13

7.2.2. Review of experience with 'Early Background Summary' 13

7.2.3. Scientific Co-ordination Board (SciCoBo) – meeting of 22 September 2016 13

7.3. Co-ordination with EMA Working Parties / Working Groups / Drafting Groups 13

7.3.1. PCWP and HCPWP membership 13

7.3.2. Extrapolation Working Group 14

7.4. Co-operation within the EU regulatory network 14

7.4.1. Environmental assessment for gene therapy products 14

7.4.2. European Medicines Agencies Group on the Co-operation on Legal and Legislative Issues (EMACOLEX) - Meeting in Uppsala (Sweden), 8 -9 September 2016 14

7.5. Co-operation with international regulators 14

7.5.1. ATMP cluster teleconference with FDA, Health Canada and PMDA (Japan) 14

7.6. CAT Work Plan 15

7.6.1. Guideline on requirements for investigational ATMPs 15

7.6.2. Questions and Answers on minimally manipulated ATMPs 15

7.6.3. CAT Workshop on cell-based cancer immunotherapies, EMA, London, 15-16 November 2016 15

7.7. Planning and reporting 15

7.7.1. Management Board data gathering exercise - CAT horizontal data collection 15

7.7.2. Planning estimates of Q3/2016 ATMP MAAs 16

7.8. Others 16

8. Any other business 16

9. Explanatory notes 17

10. List of participants 22

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants in upcoming discussions was identified.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 22 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

CAT agenda for the 06 - 07 October 2016 meeting was adopted with additions under agenda points 2.12, 4.5 and 7.2 and a correction in agenda point 2.11.2.

1.3. Adoption of the minutes

CAT minutes of the 08 - 09 September 2016 meeting were adopted with editorial corrections to agenda points 6.3.2.1, 6.3.2.5 and 6.3.2.6.

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 List of outstanding issues

No items

2.4. Day 120 Lists of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Ongoing initial full application

No items

2.7. New applications

No items

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation no. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations

2.11.1. Glybera – Alipogene tiparvovec; *Orphan*; EMA/H/C/002145/II/56

UniQure Biopharma B.V.

Rapporteur: Christiane Niederlaender; CHMP Coordinator: Greg Markey

Scope: quality: Opinion

Action: for adoption

The type II variation was adopted.

2.11.2. Strimvelis - Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence; *Orphan*; EMA/H/C/003854/II/01/G

GlaxoSmithKline Trading Services Limited

Rapporteur: Christiane Niederlaender; CHMP Coordinator: Robert J. Hemmings

Scope: quality: Opinion

Action: for adoption

The type II variation was adopted.

2.12. Other post-authorisation activities

2.12.1. Glybera - Alipogene tiparvovec; Orphan; EMEA/H/C/002145 - SOB 002.5

UniQure Biopharma B.V.

Rapporteur: Christiane Niederlaender; CHMP Coordinator: Greg Markey; PRAC Rapporteur: Julie Williams

Scope: An open label, multi-centre trial of Glybera (alipogene tiparvovec) for the treatment of LPLD Patients – Protocol amendment.
This is a phase III/IV prospective, interventional, randomised, open-label, parallel group study evaluating the clinical response as well as the dynamics of postprandial chylomicron metabolism in patients treated with Glybera with and without immunosuppressants.
Action: for adoption of the timetable

The timetable was adopted.

2.12.2. Holoclar - *ex vivo* expanded autologous human corneal epithelial cells containing stem cells; *Orphan*; EMA/H/C/002450/R/0008

Chiesi Farmaceutici S.p.A.

Rapporteur: Egbert Flory; CHMP Coordinator: Jan Mueller-Berghaus; PRAC Rapporteur: Julie Williams

Scope: one-year renewal. Opinion

Action: for adoption

The renewal of Holoclar was adopted.

2.12.3. Strimvelis – autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence; *Orphan*; EMA/H/C/003854/005 – REC005

GlaxoSmithKline Trading Services Ltd

Rapporteur: Christiane Niederlaender; CHMP Coordinator: Robert J. Hemmings

Scope: quality)

Action: for adoption

The PAM was adopted.

3. Certification of ATMPs

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinions

No items

3.2. Day 60 evaluation reports

No items

3.3. Ongoing initial application

No items

3.4. New applications

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – appointment of CAT Co-ordinators

4.1.1. Bone marrow derived mesenchymal cells (MSCs); EMA/H004688

Intended for acute graft versus host disease grades III and IV resistant to the first line of treatment

Scope: appointment of CAT Co-ordinator and adoption of timetable

Action: for adoption

Document:
Request received 22.09.16

Nominations were received. The CAT member was appointed as CAT coordinator for this procedure.

4.2. Day 30 Co-ordinators' first reports

4.2.1. Autologous bone marrow-derived non-haematopoietic stem cells; EMA/H004661/001

Intended for the treatment of multiple sclerosis

Scope: Scientific Recommendation

Action: for adoption

4.2.2. Anti-BCMA (B-cell Maturation Antigen) Chimeric Antigen Receptor T cells; EMA/H004662/001

Intended for the treatment of multiple myeloma and B cell lymphoma

Scope: Scientific Recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.3. Wharton's jelly derived mesenchymal stem cells; EMA/H004676/001

Intended for the treatment of acute myocardial infarction, chronic ischemic heart failure and no-option critical limb ischemia

Scope: Scientific Recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.4. Modified vaccinia virus Ankara encoding human mucin 1 and interleukin 2; EMA/H004658/001

Intended for the treatment of advanced non-squamous non-small cell lung cancer

Scope: Scientific Recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.5. Autologous human adipose mesenchymal stromal cells; EMA/H004677/001

Intended for the cardiac repair after myocardial infarction

Scope: Scientific Recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.6. Autologous skin cell suspension; EMA/H004679/001

Intended for the treatment of burns, donor sites and other wounds

Scope: Scientific Recommendation

Action: for adoption

CAT discussed the ATMP classification report. . CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.7. Rilimogene galvacirepved and rilimogene glafolivec; EMA/H004657/001

Intended for the treatment of metastatic, castrate-resistant Prostate cancer

Scope: Scientific Recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.3. Day 60 Co-ordinators' revised reports following List of Questions

No items

4.4. Finalisation of procedures

4.4.1. Genetically-modified *Lactobacillus reuteri* bacteria, with a plasmid containing the gene for human CXCL12-1a with an inducible promoter; EMA/H004673/001

Intended for wound healing of chronic ulcers in patients with diabetes

Scope: no comments from the EC

Action: for information

Document:
ATMP classification report

The information was noted.

4.4.2. Autologous cells of stromal vascular fraction (SVF) and autologous adipose derived stem cells; EMA/H004683/001

Intended for the treatment of treatment of cutis laxa senilis

Scope: no comments from the EC

Action: for information

Document:
ATMP classification report

The information was noted.

4.4.3. Tumour selectively replicating oncolytic adenovirus expressing tumor necrosis factor alpha (TNFα) and interleukin 2 (IL2); EMA/H004684/001

Intended for the treatment of metastatic melanoma and other solid tumors

Scope: no comments from the EC

Action: for information

Document:
ATMP classification report

The information was noted.

4.4.4. Natural killer receptor-2 autologous engineered T cells; EMA/H004680/001

Intended for the treatment of various tumour types (solid and liquid)

Scope: no comments from the EC

Action: for information

Document:
ATMP classification report

The information was noted.

4.4.5. DNA plasmid vectors encoding for human papillomavirus type 16 consensus E6 and E7 antigens and human papillomavirus (HPV) type 18 consensus E6 and E7 antigens; EMA/H004685/001

Intended for the treatment of HPV-16 and 18 related high-grade squamous intraepithelial lesions (HSIL) of the cervix and vulva

Scope: no comments from the EC

Action: for information

Document:
ATMP classification report

The information was noted.

4.5. Follow-ups and guidance

4.5.1. Informal classification discussion on request of a National Competent Authority

5. Scientific Advice

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests – appointment of CAT Co-ordinators

5.2. CAT Rapporteurs' reports

5.3. List of issues

5.4. Finalisation of Scientific Advice procedures

5.5. Follow-up of Scientific Advice procedures

No items

6. Pre-Authorisation Activities

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation for eligibility

6.3.4. Month 3 - Nomination of Rapporteurs

6.3.5. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. Strategic Review & Learning meeting

CAT Strategic Review & Learning meeting will take place in Dublin, Ireland on 24-25 October 2016

CAT: Maura O'Donovan

Scope: agreement on topics for the agenda

Action: for discussion

Document:
Draft agenda

Note: preliminary agenda/proposed topics: new medical device legislation, genetically modified organism (GMO) issue including the wording for product information, use of real world data and registries.

Note: CAT members are asked to propose agenda topics:

A last discussion of the Agenda took place. The timeslot dedicated in the agenda for in-depth reflections on the revision of the Guideline for genetically modified cells and on regulatory issue of gene editing technologies was welcomed.

7.1.2. Recommendation on criteria for competence and expertise of CAT members and alternates

Action: for discussion

Documents:
-Briefing note on competence and expertise of CAT members and alternates
-Annex B: CAT-EMA recommendation on criteria for competence and expertise of new CAT members. This annex will be added to nomination invitation letters to the Members State when a new member or alternate is to be appointed
-CAT Areas of Expertise
-CAT Criteria for Expertise and Experience

The criteria for expertise and experience of CAT members to be included with letters requesting nominations of new members/alternates was presented. CAT agreed with the proposal. Members were requested to suggest criteria to CAT secretariat by 21 October 2016.

7.1.3. GMP requirements for ATMPs

Scope: Next steps

Action: for discussion

The European Commission's representative provided feedback from the public consultation on the draft guideline on GMP requirements for ATMPs. An outline of the next steps was presented (drafting group discussion with GMP inspectors and CAT experts). The issue of the short timeline for finalisation was raised.

7.1.4. Combination packs requirements for ATMPs

Scope: in line with Notice to Applicants Chapter 1, 'combination packs' are to be understood as a combination of active substances, where the active substances are included in separate pharmaceutical forms which are included in the same package. The same document foresees that combination packs would be very exceptional and strictly related to public health, and not be for convenience or commercial purposes.

Action: for discussion

The draft eligibility criteria for combination packs were presented and CAT members were asked to consider the relevance and applicability to ATMPs. CAT members agree to contribute to a discussion group to reflect on the Regulatory paper.

7.2. Coordination with EMA Scientific Committees

7.2.1. Committee for Medicinal Products for Human Use (CHMP)

Scope: Summary of Outcomes (SoO) for the September 2016 meeting

Action: for information

Documents:
-Summary of Outcomes
The information was noted.

7.2.2. Review of experience with 'Early Background Summary'

Action: for information

Note: at the plenaries end of 2015, the committees agreed to perform a review of experience with early background summaries. A survey amongst CAT/CHMP/PRAC assessors was conducted following the pilot starting at the end of 2014.

EMA presented the experience so far with early background summaries. CAT member agreed to review the outcome the survey conducted.

7.2.3. Scientific Co-ordination Board (SciCoBo) – meeting of 22 September 2016

CAT: Paula Salmikangas

Action: for information

Documents:
Meeting documents

Paula Salmikangas provided CAT with a short feedback from the discussions that took place in the SciCoBo meeting of 22 September 2016.

7.3. Co-ordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. PCWP and HCPWP membership

Scope: call of interest for nomination of CAT representatives

Action: for appointment

CAT appointed CAT representatives for the PCWP and HCPWP:
-For the PCWP: Kieran Breen (alternate: Michele Lipucci)
-For the HCPWP: Bernd Gänsbacher (alternate: Erik Briers)

7.3.2. Extrapolation Working Group

Scope: report on public workshop on extrapolation of efficacy and safety in medicine development across age groups

Action: For information

Note: the report will be published end of October 2016.

EMA reported on the work of the 'Extrapolation Working Group'. So far the discussions were mainly on methodology and statistics in relation to age extrapolation. CAT will follow the work of the group and take part in the next steps. It was noted that the Extrapolation topic is included in the CAT workplan of 2016 (lead R Maciulaitis, members: H Ovelgönne and B Gänsbacher).

7.4. Co-operation within the EU regulatory network

7.4.1. Environmental assessment for gene therapy products

Scope: feedback by the European Commission representative

Action: for information

Note: topic discussed at the Strategic Review and Learning meeting in Utrecht (1-2 June 2016. See June 2016 CAT meeting minutes, item 7.1.1.

The European Commission representative provided an update of the discussions at the level of the Commission services and the agreement to set up a group of national experts of medicines and from the environmental authorities to discuss and agree on GMO related issues during clinical trials, marketing authorisation and post approval.

CAT members were asked to provide names of assessors/experts with experience in reviewing GMO/GTMP clinical trials. CAT members will also be involved.

7.4.2. European Medicines Agencies Group on the Co-operation on Legal and Legislative Issues (EMACOLEX) - Meeting in Uppsala (Sweden), 8 -9 September 2016

Scope: feedback by the European Commission representative

Action: for information

The European Commission's representative reported from the recent discussions at the EMACOLEX meeting on ATMPs. It was agreed to set up a working group of EMACOLEX to discuss specific ATMP related questions (for agreement by the Heads of Medicines Agencies). Three questionnaires were sent by the Commission to the EMACOLEX members to gather the member state views. CAT members could be asked by their legal colleagues to provide assistance in completing these questionnaires.

7.5. Co-operation with international regulators

7.5.1. ATMP cluster teleconference with FDA, Health Canada and PMDA (Japan)

The teleconference will take place during the plenary meeting on Thursday 6 October from 14.00hrs – 15.00hrs

CAT resource: Paula Salmikangas

Action: for adoption

Document table:
Agenda

The agenda was adopted.

7.6. CAT Work Plan

7.6.1. Guideline on requirements for investigational ATMPs

CAT drafting groups: Tiina Palomäki (Rapporteur), Ilona Reischl (Rapporteur), Metoda Lipnik-Stangelj, Margarida Menezes Ferreira, Maura O'Donovan, Simona Badoi, Tomáš Boráň, Christiane Niederlaender, Paolo Gasparini, Olli Tenhunen, Marit Hystad, Violaine Closson-Carella, Marcel Hoefnagel, Guido Pantè, Carla Herberts

Scope: feedback from the break-out meeting held on 5 and 6 October 2016

Action: for information

Feedback was provided on the development of the guideline: the non-clinical and clinical parts of the guideline are close to finalisation and the aim is to have a first presentation of these parts to the CAT in November 2016. The quality part of the guideline will take some more time before finalisation.

7.6.2. Questions and Answers on minimally manipulated ATMPs

CAT drafting group: Metoda Lipnik-Stangelj, Paula Salmikangas, Tiina Palomäki, Egbert Flory, Margarida Menezes Ferreira, Marit Hystad, Mikuláš Hrubiško

Scope: feedback on the break-out meeting held on 5 and 6 October 2016

Action: for information

Note:
The Questions-and-Answers will describe the quality, non-clinical and clinical requirements for the marketing authorisation for a minimally manipulated ATMP (e.g. CD34+ cells for cardiac repair). In the answers, a practical explanation will be provided on how to use the risk based approach to identify and justify deviations for the standard requirements for cell-based ATMPs as included in Annex I Part IV of Dir. 2001/83/EC.

Feedback was provided on the development of this Q&A document. Some final drafting and editorial changes will take place this month so that a draft can be presented and discussed at the CAT in November 2016.

7.6.3. CAT Workshop on cell-based cancer immunotherapies, EMA, London, 15-16 November 2016

CAT resources: Rune Kjeken, Björn Carlsson

Action: for information

CAT members who did not apply to join the workshop in person are encouraged to follow the meeting via the broadcast.

7.7. Planning and reporting

7.7.1. Management Board data gathering exercise - CAT horizontal data collection

Postponed to November 2016

Scope: Update on progress. The project started in March 2014 to gather evidence needed by the European Commission in drafting future legislative proposal on fees. The goal was to assemble evidence about the time spent on procedures at EMA and NCAs. The latest part of the projects relate to time spent by Committee members/alternates when not acting in their principal role as centralised product rapporteurs/peer reviewers.

Action: For information

7.7.2. Planning estimates of Q3/2016 ATMP MAAs

Action: for information

The information was noted.

7.8. Others

No items

8. Any other business

No items

Date of next CAT meeting:
Thursday 03 to Friday 04 November 2016

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

HCPWP: Healthcare Professionals' Working Party

HTA: Health Technology Assessment Bodies

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Applicant

MAH: Marketing Authorisation Holder

MSC: Mesenchymal stem cells

PAM: Post-authorisation measure

PCWP: Patients' and Consumers' Working Party

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee

PRIME: Priority Medicines

RMP: Risk Management Plan

RP: Reflection paper

RSI: Request for supplementary information

SA: Scientific Advice

SAG-O: Scientific Advisory Group Oncology

SAWP: Scientific Advice Working Party

SR: Summary Report

SWP: Safety Working Party

SME: Small and medium size enterprises

SmPC: Summary of Products Characteristics

TT: Timetable

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (*section 2.9*) and Post-authorisation activities (*section 2.10*).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

10. List of participants

including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 06 – 07 October 2016 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Paula Salmikangas	Chair	Finland	No interests declared	
Ilona Reischl	Member	Austria	No interests declared	
Claire Beuneu	Member	Belgium	No interests declared	
Belaïd Sekkali	Alternate	Belgium	No interests declared	
Mirna Golemovic	Member	Croatia	No interests declared	
Ivana Haunerova	Alternate	Czech Republic	No interests declared	
Nanna Aaby Kruse	Member	Denmark	No restrictions applicable to this meeting	
Tarmo Tiido	Alternate	Estonia	No interests declared	
Tiina Palomäki	Member	Finland	No interests declared	
Olli Tenhunen	Alternate	Finland	No interests declared	
Violaine Closson	Member	France	No interests declared	
Martina Schüssler-Lenz	Member (Vice-Chair) – via TC	Germany	No interests declared	
Egbert Flory	Alternate	Germany	No interests declared	
Angeliki Roboti	Alternate	Greece	No interests declared	
Krisztian Fodor	Member	Hungary	No interests declared	
Maura O'Donovan	Member	Ireland	No interests declared	
Una Riekstina	Member	Latvia	No interests declared	
Anthony Samuel	Alternate (to CHMP representative)	Malta	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Johannes Hendrikus Ovelgönne	Member	Netherlands	No interests declared	
Rune Kjeken	Alternate	Norway	No restrictions applicable to this meeting	
Dariusz Śladowski	Member	Poland	No restrictions applicable to this meeting	
Margarida Menezes-Ferreira	Alternate (to CHMP representative)	Portugal	No interests declared	
Simona Badoi	Member	Romania	No interests declared	
Mikuláš Hrubiško	Member	Slovakia	No restrictions applicable to this meeting	
Metoda Lipnik-Stangelj	Member	Slovenia	No interests declared	
Sol Ruiz	Member (CHMP co-opted member) – via TC	Spain	No interests declared	
Marcos Timón	Alternate (to CHMP representative)	Spain	No interests declared	
Lennart Åkerblom	Member	Sweden	No interests declared	
Björn Carlsson	Alternate	Sweden	No interests declared	
James McBlane	Alternate	United Kingdom	No interests declared	
Marc Turner	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Bernd Gänsbacher	Member	Healthcare Professionals' Representative	No interests declared	
Kieran Breen	Member	Patients' Representative	No restrictions applicable to this meeting	
Michelino	Alternate	Patients'	No restrictions	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Lipucci di Paola		Representative	applicable to this meeting	
Mariëtte Driessens	Member	Patients' Representative	No restrictions applicable to this meeting	
Erik Briers	Alternate	Patients' Representative	No restrictions applicable to this meeting	
Anne Pastoft	Expert	Denmark	No interests declared	
Louise Bisset	Expert - via telephone*	United Kingdom	No interests declared	
Veronika Ganeva	Expert - via telephone*	United Kingdom	No interests declared	
Wiebke Hoppensack	Expert – via telephone	Germany	No interests declared	
A representative from the European Commission attended the meeting				
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the agenda topics or activities they participated in.